NewAmsterdam Pharma names new accounting officer, details COO exit terms
The company appointed Robert W. Gunning as principal accounting officer while finalizing separation and advisory terms for former COO Douglas Kling.
SEC filing (2)
Latest
5 stories
Monday, September 28
Friday, August 14
Wednesday, August 5
NewAmsterdam reports positive CHMP opinion for obicetrapib, sets PREVAIL and RUBENS timelines
The company said an EMA committee backed marketing authorization for obicetrapib and its ezetimibe combination, while cash stood at $678.3 million as of June 30, 2026.
SEC filing
Friday, July 24
NewAmsterdam and Menarini get positive EU CHMP opinion for obicetrapib medicines
The European Medicines Agency committee backed marketing authorization for two obicetrapib-based cholesterol drugs, with a final European Commission decision expected in the second half of 2026.
SEC filing
Wednesday, July 22
NewAmsterdam Pharma's COO Kling to resign, take CEO role elsewhere
Douglas Kling will step down as chief operating officer effective August 14, 2026, and is expected to advise on the company's obicetrapib trial work under a separate agreement.
SEC filing